NYSE:BCR - C R Bard Stock Price, Price Target & More

$331.24 0.00 (0.00 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$331.24
Today's Range$331.24 - $331.24
52-Week Range$222.42 - $337.73
VolumeN/A
Average Volume679,456 shs
Market Capitalization$24.14 billion
P/E RatioN/A
Dividend Yield0.23%
Beta0.52

About C R Bard (NYSE:BCR)

C R Bard logoC. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive BCR News and Ratings via Email

Sign-up to receive the latest news and ratings for BCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNYSE:BCR
CUSIP06738310
Phone+1-908-2778000

Debt

Debt-to-Equity Ratio0.57%
Current Ratio1.72%
Quick Ratio1.37%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio27.86
P/E Growth2.53

Sales & Book Value

Annual Sales$3.71 billion
Price / Sales6.50
Cash Flow$13.4760 per share
Price / Cash24.58
Book Value$22.78 per share
Price / Book14.54

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$531.40 million
Net Margins9.51%
Return on Equity19.39%
Return on Assets6.91%

Miscellaneous

Employees16,300
Outstanding Shares72,890,000

How to Become a New Pot Stock Millionaire

C R Bard (NYSE:BCR) Frequently Asked Questions

What is C R Bard's stock symbol?

C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."

How often does C R Bard pay dividends? What is the dividend yield for C R Bard?

C R Bard announced a quarterly dividend on Wednesday, October 11th. Stockholders of record on Friday, December 8th will be paid a dividend of $0.26 per share on Friday, December 29th. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 7th. View C R Bard's Dividend History.

How were C R Bard's earnings last quarter?

C R Bard Inc (NYSE:BCR) announced its quarterly earnings data on Wednesday, October, 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to analysts' expectations of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.64 EPS. View C R Bard's Earnings History.

What price target have analysts set for BCR?

7 brokers have issued 1-year target prices for C R Bard's stock. Their forecasts range from $265.00 to $337.00. On average, they expect C R Bard's share price to reach $310.60 in the next twelve months. View Analyst Ratings for C R Bard.

What are Wall Street analysts saying about C R Bard stock?

Here are some recent quotes from research analysts about C R Bard stock:
  • 1. According to Zacks Investment Research, "In the last year, C. R. Bard has outperformed the broader industry trends with respect to price performance. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth. " (12/26/2017)
  • 2. Needham & Company LLC analysts commented, "BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat to 5.0% in 3Q17 from 6.4% in 2Q17 as three of four segments missed consensus. Revenue growth faced a 1.5% headwind, attributable to the impact from the hurricanes and a Surgical Sealant supply issue, both equally. We have maintained our revenue and EPS estimates." (10/26/2017)

Who are some of C R Bard's key competitors?

Who are C R Bard's key executives?

C R Bard's management team includes the folowing people:
  • Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
  • John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
  • James C. Beasley, Group President (Age 53)
  • Timothy P. Collins, Group President (Age 56)
  • John P. Groetelaars, Group President (Age 50)
  • Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
  • Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
  • John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
  • Frank Lupisella Jr., Vice President, Controller (Age 56)
  • Betty D. Larson, Vice President - Human Resources (Age 41)

Has C R Bard been receiving favorable news coverage?

News articles about BCR stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. C R Bard earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news stories about the medical instruments supplier an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of C R Bard?

Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is C R Bard's stock price today?

One share of BCR stock can currently be purchased for approximately $331.24.

How big of a company is C R Bard?

C R Bard has a market capitalization of $24.14 billion and generates $3.71 billion in revenue each year. C R Bard employs 16,300 workers across the globe.

How can I contact C R Bard?

C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000.


MarketBeat Community Rating for C R Bard (BCR)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  504 (Vote Underperform)
Total Votes:  784
MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

C R Bard (NYSE:BCR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for C R Bard in the last 12 months. Their average twelve-month price target is $310.60, suggesting that the stock has a possible downside of 6.23%. The high price target for BCR is $337.00 and the low price target for BCR is $265.00. There are currently 8 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.22
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $310.60$310.60$301.3333$282.2857
Price Target Upside: 6.23% downside7.01% downside9.78% downside11.87% downside

C R Bard (NYSE:BCR) Consensus Price Target History

Price Target History for C R Bard (NYSE:BCR)

C R Bard (NYSE:BCR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017BarclaysBoost Price TargetEqual Weight$245.00 -> $337.00N/AView Rating Details
11/3/2017CowenReiterated RatingHold$317.00N/AView Rating Details
10/26/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
9/14/2017Jefferies GroupReiterated RatingHold$317.00MediumView Rating Details
7/11/2017BMO Capital MarketsReiterated RatingHold$317.00LowView Rating Details
4/26/2017Raymond JamesDowngradeStrong-Buy -> Mkt PerformLowView Rating Details
4/25/2017Wells FargoDowngradeOutperform -> Market PerformLowView Rating Details
4/24/2017Morgan StanleyDowngradeOverweight -> Equal WeightLowView Rating Details
1/27/2017JMP SecuritiesBoost Price Target$240.00 -> $255.00N/AView Rating Details
1/5/2017UBSUpgradeOutperform -> Strong-BuyN/AView Rating Details
9/15/2016Evercore ISIInitiated CoverageBuy$235.00N/AView Rating Details
7/28/2016Leerink SwannReiterated RatingMarket Perform$240.00 -> $233.00N/AView Rating Details
7/27/2016JPMorgan ChaseBoost Price TargetNeutral$214.00 -> $225.00N/AView Rating Details
7/27/2016CitigroupBoost Price TargetBuy$241.00 -> $265.00N/AView Rating Details
7/27/2016Deutsche BankBoost Price TargetHold$234.00 -> $240.00N/AView Rating Details
7/8/2016Bank of AmericaDowngradeBuy -> NeutralN/AView Rating Details
5/24/2016Piper JaffrayReiterated RatingBuy$241.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

C R Bard (NYSE:BCR) Earnings History and Estimates Chart

Earnings by Quarter for C R Bard (NYSE:BCR)

C R Bard (NYSE:BCR) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$2.88$2.88$2.88
Q2 20181$3.12$3.12$3.12
Q3 20181$3.19$3.19$3.19

C R Bard (NYSE BCR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017Q3 2017$2.96$3.02$990.64 million$989.80 millionViewN/AView Earnings Details
7/27/2017Q2 2017$2.84$2.92$976.53 million$979.70 millionViewN/AView Earnings Details
4/23/2017Q1 2017$2.65$2.87$916.15 million$938.80 millionViewN/AView Earnings Details
1/26/2017Q416$2.74$2.77$956.12 million$967.10 millionViewListenView Earnings Details
10/25/2016Q3$2.55$2.64$931.66 million$941.90 millionViewListenView Earnings Details
7/26/2016Q2$2.47$2.54$915.22 million$931.50 millionViewListenView Earnings Details
4/27/2016Q116$2.17$2.34$845.77 million$873.50 millionViewListenView Earnings Details
1/28/2016Q415$2.41$2.43$867.22 million$870.80 millionViewListenView Earnings Details
10/22/2015Q3$2.24$2.28$852.93 million$865.70 millionViewListenView Earnings Details
7/23/2015Q2$2.18$2.27$836.18 million$859.80 millionViewListenView Earnings Details
4/23/2015Q115$2.07$2.10$813.36 million$819.70 millionViewListenView Earnings Details
1/29/2015Q414$2.24$2.29$855.11 million$867.20 millionViewListenView Earnings Details
10/22/2014Q314$2.10$2.15$819.20 million$830.00 millionViewListenView Earnings Details
7/24/2014Q214$2.00$2.06$814.58 million$827.10 millionViewListenView Earnings Details
4/22/2014Q114$1.86$1.91$787.10 million$799.30 millionViewListenView Earnings Details
1/30/2014Q413$1.41$1.42$782.28 million$791.30 millionViewListenView Earnings Details
10/22/2013Q313$1.40$1.50$739.12 million$758.00 millionViewListenView Earnings Details
7/23/2013Q2 2013$1.38$1.42$750.91 million$759.90 millionViewListenView Earnings Details
4/23/2013Q1 2013$1.42$1.44$728.45 million$740.30 millionViewListenView Earnings Details
1/31/2013Q4 2012$1.67$1.70$757.49 million$762.60 millionViewListenView Earnings Details
10/23/2012$1.64$1.64ViewN/AView Earnings Details
7/25/2012$1.64$1.62ViewN/AView Earnings Details
4/24/2012Q1 2012$1.57$1.61ViewN/AView Earnings Details
1/31/2012$1.68$1.70ViewN/AView Earnings Details
10/25/2011$1.60$1.62ViewN/AView Earnings Details
7/21/2011$1.57$1.57ViewN/AView Earnings Details
4/21/2011$1.46$1.51ViewN/AView Earnings Details
1/31/2011$1.48$1.54ViewN/AView Earnings Details
10/21/2010Q3 2010$1.40$1.43ViewN/AView Earnings Details
7/22/2010Q2 2010$1.36$1.39ViewN/AView Earnings Details
4/22/2010Q1 2010$1.24$1.25ViewN/AView Earnings Details
1/28/2010Q4 2009$1.34$1.39ViewN/AView Earnings Details
10/21/2009Q3 2009$1.27$1.31ViewN/AView Earnings Details
7/22/2009Q2 2009$1.21$1.23ViewN/AView Earnings Details
4/22/2009Q1 2009$1.17$1.17ViewN/AView Earnings Details
1/29/2009Q4 2008$1.18$1.19ViewN/AView Earnings Details
10/22/2008Q3 2008$1.08$1.10ViewN/AView Earnings Details
7/23/2008Q2 2008$1.08$1.10ViewN/AView Earnings Details
4/23/2008Q1 2008$1.05$1.06ViewN/AView Earnings Details
1/31/2008Q4 2007$0.99$1.01ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

C R Bard (NYSE:BCR) Dividend Information

C R Bard pays an annual dividend of $0.78 per share, with a dividend yield of 0.24%. BCR's most recent quarterly dividend payment was Friday, December 29. The company has grown its dividend for the last 46 consecutive years and is increasing its dividend by an average of 6.50% each year.
Most Recent Dividend:12/29/2017
Annual Dividend:$0.78
Dividend Yield:0.24%
Dividend Growth:6.50% (3 Year Average)
Payout Ratio:6.56% (Based on This Year's Estimates)
6.01% (Based on Next Year's Estimates)
Track Record:46 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for C R Bard (NYSE:BCR)

C R Bard (NYSE:BCR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/11/2017quarterly$0.260.32%12/7/201712/8/201712/29/2017
6/14/2017quarterly$0.260.33%7/20/20177/24/20178/4/2017
4/19/2017quarterly$0.260.41%4/27/20175/1/20175/12/2017
12/14/2016quarterly$0.260.47%1/19/20171/23/20172/3/2017
10/12/2016quarterly$0.260.48%10/20/201610/24/201611/4/2016
6/8/2016quarterly$0.260.46%7/14/20167/18/20167/29/2016
4/20/2016quarterly$0.240.46%4/28/20165/2/20165/13/2016
12/9/2015quarterly$0.240.52%1/21/20161/25/20162/5/2016
10/14/2015quarterly$0.240.5%10/22/201510/26/201511/6/2015
6/10/2015quarterly$0.240.56%7/16/20157/20/20157/31/2015
4/15/2015quarterly$0.220.52%4/23/20154/27/20155/8/2015
12/10/2014quarterly$0.220.52%1/22/20151/26/20152/6/2015
10/8/2014quarterly$0.220.59%10/16/201410/20/201410/31/2014
6/11/2014quarterly$0.220.62%7/17/20147/21/20148/1/2014
4/16/2014quarterly$0.210.6%4/24/20144/28/20145/9/2014
12/11/2013quarterly$0.210.63%1/16/20141/21/20141/31/2014
10/9/2013quarterly$0.210.72%10/17/201310/21/201311/1/2013
6/12/2013quarterly$0.210.77%7/18/20137/22/20138/2/2013
4/17/2013quarterly$0.200.8%4/25/20134/29/20135/10/2013
12/12/2012quarterly$0.200.83%1/17/20131/22/20132/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

C R Bard (NYSE BCR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 79.11%
Insider Trading History for C R Bard (NYSE:BCR)
Insider Trading History for C R Bard (NYSE:BCR)

C R Bard (NYSE BCR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/20/2017John A. DefordVPSell14,107$333.48$4,704,402.36View SEC Filing  
12/14/2017Jim C BeasleyInsiderSell3,395$332.00$1,127,140.0025,630View SEC Filing  
12/11/2017Jim C BeasleyInsiderSell15,044$332.00$4,994,608.00View SEC Filing  
11/7/2017John H WeilandVice ChairmanSell33,435$333.31$11,144,219.8576,331View SEC Filing  
11/2/2017Christopher S. HollandInsiderSell38,242$334.04$12,774,357.68View SEC Filing  
11/2/2017Frank Lupisella JrVPSell7,035$334.70$2,354,614.5013,824View SEC Filing  
10/30/2017David M. BarrettDirectorSell3,344$327.31$1,094,524.64View SEC Filing  
10/20/2017Betty D LarsonVPSell5,906$330.16$1,949,924.9610,753View SEC Filing  
10/18/2017Frank Lupisella, Jr.VPSell9,173$325.00$2,981,225.00View SEC Filing  
10/12/2017Timothy P CollinsInsiderSell55,818$322.03$17,975,070.54View SEC Filing  
10/9/2017Timothy P CollinsInsiderSell8,388$322.00$2,700,936.00View SEC Filing  
9/29/2017Sharon M. LuboffInsiderSell30,252$320.00$9,680,640.00View SEC Filing  
8/10/2017John P GroetelaarsInsiderSell23,687$318.73$7,549,757.5131,445View SEC Filing  
4/24/2017Frank Lupisella JrVPSell3,622$304.00$1,101,088.0010,139View SEC Filing  
2/21/2017Jim C BeasleyInsiderSell4,390$245.00$1,075,550.0026,625View SEC Filing  
2/14/2017John A DefordVPSell2,788$240.51$670,541.8824,684View SEC Filing  
2/14/2017John H WeilandVice ChairmanSell14,091$240.49$3,388,744.5968,978View SEC Filing  
2/14/2017John P GroetelaarsInsiderSell732$240.49$176,038.6819,695View SEC Filing  
2/14/2017Timothy M RingChairmanSell14,425$240.50$3,469,212.50100,283View SEC Filing  
2/13/2017John A. DefordVPSell469$240.07$112,592.83View SEC Filing  
2/13/2017John H WeilandVice ChairmanSell1,274$240.00$305,760.0070,033View SEC Filing  
2/13/2017Timothy M RingChairmanSell1,767$240.02$424,115.34103,906View SEC Filing  
2/13/2017Timothy P CollinsInsiderSell642$240.30$154,272.6034,515View SEC Filing  
2/10/2017Betty D LarsonVPSell3,292$240.92$793,108.648,399View SEC Filing  
2/9/2017Jim C BeasleyInsiderSell8,593$239.58$2,058,710.9434,415View SEC Filing  
2/9/2017John A. DefordVPSell5,816$239.58$1,393,397.28View SEC Filing  
2/9/2017John H WeilandVice ChairmanSell14,281$239.54$3,420,870.7483,613View SEC Filing  
2/9/2017Timothy M RingChairmanSell20,324$239.56$4,868,817.44127,954View SEC Filing  
1/31/2017Gail K NaughtonDirectorSell367$236.22$86,692.741,620View SEC Filing  
1/11/2017John P GroetelaarsInsiderSell573$235.00$134,655.0016,554View SEC Filing  
1/10/2017Frank Lupisella, Jr.VPSell2,945$232.00$683,240.00View SEC Filing  
1/9/2017Frank Lupisella, Jr.VPSell210$232.00$48,720.00View SEC Filing  
12/30/2016Frank Lupisella JrVPSell237$226.00$53,562.0014,520View SEC Filing  
12/30/2016Jim C BeasleyInsiderSell4,709$225.00$1,059,525.0027,378View SEC Filing  
12/12/2016John A. DefordVPSell15,883$218.03$3,462,970.49View SEC Filing  
12/12/2016John H WeilandVice ChairmanSell11,190$219.67$2,458,107.3072,780View SEC Filing  
12/12/2016Sharon M. LuboffInsiderSell6,000$219.00$1,314,000.00View SEC Filing  
10/28/2016Christopher S. HollandInsiderSell5,724$211.12$1,208,450.88View SEC Filing  
9/28/2016Timothy M RingChairmanSell92,293$227.81$21,025,268.33145,876View SEC Filing  
9/26/2016Timothy M RingChairmanSell110,000$228.96$25,185,600.0096,030View SEC Filing  
9/19/2016Betty D LarsonVPSell4,032$225.33$908,530.5610,298View SEC Filing  
9/6/2016John A. DefordVPSell7,928$221.06$1,752,563.68View SEC Filing  
5/27/2016Christopher S HollandCFOSell3,970$219.89$872,963.3031,306View SEC Filing  
5/17/2016John P GroetelaarsInsiderSell1,162$219.88$255,500.5617,431View SEC Filing  
5/12/2016Tommy G ThompsonDirectorSell500$219.52$109,760.007,036View SEC Filing  
5/5/2016Tony L WhiteDirectorSell1,200$216.19$259,428.0014,671View SEC Filing  
4/28/2016Jim C BeasleyInsiderSell4,709$215.00$1,012,435.0027,378View SEC Filing  
4/27/2016Sharon M LuboffVPSell10,000$210.00$2,100,000.0033,706View SEC Filing  
3/29/2016Christopher S HollandCFOSell1,650$200.00$330,000.0027,335View SEC Filing  
2/25/2016Jim C BeasleyInsiderSell1,113$195.27$217,335.5122,669View SEC Filing  
2/23/2016Frank Lupisella JrVPSell2,300$190.25$437,575.0014,495View SEC Filing  
2/22/2016Christopher S HollandCFOSell618$190.00$117,420.0028,985View SEC Filing  
2/22/2016Patricia G ChristianVPSell3,182$190.00$604,580.009,240View SEC Filing  
2/17/2016John A. DefordVPSell661$187.44$123,897.8421,607View SEC Filing  
2/17/2016John H. WeilandCOOSell1,618$187.45$303,294.1061,590View SEC Filing  
2/17/2016Timothy M. RingCEOSell2,453$187.62$460,231.8697,370View SEC Filing  
2/17/2016Timothy P. CollinsinsiderSell974$187.48$182,605.5229,276View SEC Filing  
2/16/2016Anthony WeltersDirectorSell1,784$187.47$334,446.481,908View SEC Filing  
2/12/2016Christopher S. HollandCFOSell6,297$181.08$1,140,260.7629,603View SEC Filing  
2/12/2016John A. DefordVPSell6,400$182.40$1,167,360.0022,855View SEC Filing  
2/12/2016John H. WeilandCOOSell15,632$182.86$2,858,467.5264,603View SEC Filing  
2/12/2016Timothy M. RingCEOSell24,003$182.76$4,386,788.28102,200View SEC Filing  
2/12/2016Timothy P. CollinsinsiderSell7,893$182.28$1,438,736.0431,435View SEC Filing  
2/10/2016John P. GroetelaarsinsiderSell3,319$187.16$621,184.0418,841View SEC Filing  
2/9/2016John A. DefordVPSell3,407$180.62$615,372.3418,710View SEC Filing  
2/9/2016John H. WeilandCOOSell8,898$181.10$1,611,427.8053,078View SEC Filing  
2/9/2016Timothy M. RingCEOSell4,836$181.20$876,283.2093,896View SEC Filing  
2/9/2016Timothy P. CollinsinsiderSell4,205$181.24$762,114.2025,076View SEC Filing  
2/2/2016Tommy G ThompsonDirectorSell2,319$188.75$437,711.256,536View SEC Filing  
12/16/2015John H. WeilandCOOSell19,686$188.49$3,710,614.1467,409View SEC Filing  
12/16/2015Patricia G ChristianVPSell1,908$190.00$362,520.009,413View SEC Filing  
12/14/2015Jim C. BeasleyinsiderSell20,577$184.78$3,802,218.0624,313View SEC Filing  
12/14/2015John A. DefordVPSell5,627$184.00$1,035,368.0023,646View SEC Filing  
12/14/2015John H. WeilandCOOSell33,569$184.25$6,185,088.2573,505View SEC Filing  
11/30/2015Timothy M. RingCEOSell22,052$187.37$4,131,883.24119,694View SEC Filing  
10/29/2015Timothy M. RingCEOSell30,543$184.79$5,644,040.97119,694View SEC Filing  
10/27/2015Gail K. NaughtonDirectorSell2,458$181.99$447,331.421,556View SEC Filing  
9/29/2015Timothy M. RingCEOSell40,000$185.16$7,406,400.00119,694View SEC Filing  
8/31/2015Timothy M. RingCEOSell40,000$195.17$7,806,800.00119,694View SEC Filing  
8/18/2015Sharon M. LuboffVPSell2,374$199.76$474,230.2428,399View SEC Filing  
8/17/2015Sharon M LuboffVPSell2,030$200.00$406,000.00View SEC Filing  
8/14/2015Tommy G ThompsonDirectorSell1,200$199.25$239,100.00View SEC Filing  
7/13/2015John P GroetelaarsInsiderSell2,456$175.00$429,800.00View SEC Filing  
7/13/2015Timothy M RingCEOSell20,000$176.04$3,520,800.00View SEC Filing  
4/28/2015Tommy G ThompsonDirectorSell1,200$170.43$204,516.00View SEC Filing  
3/23/2015Timothy M RingCEOSell7,628$170.65$1,301,718.20View SEC Filing  
2/23/2015Timothy M RingCEOSell20,000$176.33$3,526,600.00View SEC Filing  
2/19/2015Jim C BeasleyInsiderSell2,884$174.79$504,094.36View SEC Filing  
2/19/2015John H WeilandCOOSell8,413$174.99$1,472,190.87View SEC Filing  
2/19/2015John P GroetelaarsVPSell4,566$175.14$799,689.24View SEC Filing  
2/17/2015Jim C BeasleyInsiderSell9,904$174.58$1,729,040.32View SEC Filing  
2/17/2015John A DefordVPSell6,146$174.58$1,072,968.68View SEC Filing  
2/17/2015John H WeilandCOOSell13,616$174.51$2,376,128.16View SEC Filing  
2/17/2015Timothy M RingCEOSell6,284$174.75$1,098,129.00View SEC Filing  
2/12/2015Patricia G ChristianVPSell1,408$173.97$244,949.76View SEC Filing  
2/12/2015Timothy M RingCEOSell14,363$173.74$2,495,427.62View SEC Filing  
2/12/2015Timothy P CollinsInsiderSell6,564$174.00$1,142,136.00View SEC Filing  
2/9/2015Anthony WeltersDirectorSell1,563$169.02$264,178.26View SEC Filing  
1/22/2015Timothy M RingCEOSell20,000$177.84$3,556,800.00View SEC Filing  
12/22/2014Timothy M RingCEOSell32,325$169.64$5,483,613.00View SEC Filing  
12/17/2014Jim C BeasleyInsiderSell4,525$168.42$762,100.50View SEC Filing  
12/17/2014Sharon M LuboffVPSell3,564$168.36$600,035.04View SEC Filing  
12/16/2014Jim C BeasleyInsiderSell14,634$167.47$2,450,755.98View SEC Filing  
12/16/2014John A DefordVPSell5,626$167.47$942,186.22View SEC Filing  
12/16/2014John H WeilandCOOSell23,093$166.74$3,850,526.82View SEC Filing  
12/16/2014Timothy M RingCEOSell15,232$166.60$2,537,651.20View SEC Filing  
12/15/2014John H WeilandCOOSell13,589$166.56$2,263,383.84View SEC Filing  
12/10/2014Patricia G ChristianVPSell1,269$169.20$214,714.80View SEC Filing  
12/9/2014John H WeilandCOOSell6,350$170.32$1,081,532.00View SEC Filing  
12/9/2014Timothy M RingCEOSell9,550$170.20$1,625,410.00View SEC Filing  
10/27/2014Sharon M LuboffVPSell10,000$158.80$1,588,000.00View SEC Filing  
10/22/2014Timothy M RingCEOSell60,000$149.07$8,944,200.00View SEC Filing  
10/6/2014Timothy M RingCEOSell60,000$148.00$8,880,000.00View SEC Filing  
9/10/2014John H WeilandCOOSell27,179$149.50$4,063,260.50View SEC Filing  
9/2/2014Timothy M RingCEOSell10,228$148.83$1,522,233.24View SEC Filing  
8/4/2014Bronwen K KellyVPSell10,055$150.25$1,510,763.75View SEC Filing  
8/1/2014Timothy M RingCEOSell10,231$149.04$1,524,828.24View SEC Filing  
7/30/2014Timothy P CollinsInsiderSell30,914$150.38$4,648,847.32View SEC Filing  
7/29/2014Sharon M LuboffVPSell5,115$151.37$774,257.55View SEC Filing  
7/1/2014Timothy M RingCEOSell10,231$144.30$1,476,333.30View SEC Filing  
6/2/2014Timothy M RingCEOSell10,231$147.50$1,509,072.50View SEC Filing  
3/3/2014Timothy RingCEOSell10,231$142.23$1,455,155.13172,216View SEC Filing  
2/27/2014Sharon LuboffVPSell9,914$144.86$1,436,142.0436,958View SEC Filing  
2/20/2014Frank Lupisella, Jr.VPSell2,520$140.26$353,455.2018,122View SEC Filing  
2/18/2014Marc BreslawskyDirectorSell2,400$141.34$339,216.0012,914View SEC Filing  
2/11/2014John WeilandCOOSell9,328$135.32$1,262,264.96115,695View SEC Filing  
2/11/2014Sharon LuboffVPSell1,400$135.00$189,000.0039,357View SEC Filing  
1/16/2014John WeilandCOOSell81,500$136.13$11,094,595.00133,483View SEC Filing  
1/13/2014Sharon LuboffVPSell2,500$135.00$337,500.0042,381View SEC Filing  
12/12/2013Jim BeasleyInsiderSell9,802$133.98$1,313,271.9639,493View SEC Filing  
12/12/2013John DefordVPSell2,792$133.98$374,072.1633,543View SEC Filing  
12/10/2013John WeilandCOOSell10,389$137.30$1,426,409.70123,994View SEC Filing  
12/10/2013Timothy RingCEOSell15,623$137.12$2,142,225.76178,568View SEC Filing  
12/2/2013Timothy RingCEOSell10,231$138.85$1,420,574.35209,323View SEC Filing  
11/6/2013David BarrettDirectorSell1,600$138.13$221,008.002,547View SEC Filing  
10/28/2013Herbert L HenkelDirectorSell2,400$134.66$323,184.00View SEC Filing  
10/28/2013Sharon M AlterioVPSell14,002$134.91$1,889,009.82View SEC Filing  
10/23/2013John H WeilandCOOSell60,210$134.01$8,068,742.10View SEC Filing  
10/21/2013John H WeilandCOOSell84,525$125.62$10,618,030.50View SEC Filing  
10/21/2013Timothy M RingCEOSell8,313$125.52$1,043,447.76View SEC Filing  
10/18/2013Gary D DolchVPSell10,000$125.00$1,250,000.00View SEC Filing  
9/24/2013Timothy RingCEOSell8,313$117.77$979,022.01209,323View SEC Filing  
9/9/2013John A DefordVPSell28,364$117.89$3,343,831.96View SEC Filing  
9/3/2013Timothy RingCEOSell10,231$114.65$1,172,984.15209,323View SEC Filing  
8/30/2013Jim BeasleyInsiderSell1,420$115.33$163,768.6041,022View SEC Filing  
8/21/2013Timothy RingCEOSell8,313$113.24$941,364.12209,323View SEC Filing  
8/12/2013Sharon AlterioVPSell13,379$117.01$1,565,476.7947,032View SEC Filing  
8/5/2013Brian P KellyVPSell28,000$115.69$3,239,320.00View SEC Filing  
8/2/2013David M BarrettDirectorSell1,200$115.70$138,840.00View SEC Filing  
8/2/2013Frank Lupisella JrVPSell10,500$115.61$1,213,905.00View SEC Filing  
8/1/2013John H WeilandCOOSell87,336$115.35$10,074,207.60View SEC Filing  
7/29/2013Timothy P CollinsInsiderSell22,025$113.60$2,502,040.00View SEC Filing  
7/26/2013Anthony WeltersDirectorSell5,600$113.12$633,472.00View SEC Filing  
7/26/2013Jean F HollowayVPSell2,275$113.52$258,258.00View SEC Filing  
7/22/2013Timothy M RingCEOSell8,312$113.58$944,076.96View SEC Filing  
6/21/2013Timothy M RingCEOSell8,312$110.05$914,735.60View SEC Filing  
6/20/2013Gary D DolchVPSell14,569$109.97$1,602,152.93View SEC Filing  
5/21/2013Timothy M RingCEOSell8,312$106.65$886,474.80View SEC Filing  
5/20/2013Marc C BreslawskyDirectorSell2,400$107.20$257,280.00View SEC Filing  
5/8/2013Timothy M RingCEOSell8,312$102.00$847,824.00View SEC Filing  
4/11/2013G Mason MorfitInsiderSell300,000$102.47$30,741,000.00View SEC Filing  
4/9/2013Timothy M RingCEOSell8,312$102.00$847,824.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

C R Bard (NYSE BCR) News Headlines

Source:
DateHeadline
C R Bard (BCR) Receives Hold Rating from BMO Capital MarketsC R Bard (BCR) Receives Hold Rating from BMO Capital Markets
www.americanbankingnews.com - April 19 at 5:50 PM
C R Bard (BCR) Downgraded by Zacks Investment Research to HoldC R Bard (BCR) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 17 at 10:55 PM
C R Bard (BCR) Downgraded by BidaskClub to BuyC R Bard (BCR) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - April 17 at 4:17 PM
C R Bards (BCR) Hold Rating Reiterated at Jefferies GroupC R Bard's (BCR) Hold Rating Reiterated at Jefferies Group
www.americanbankingnews.com - April 13 at 11:42 PM
Hernia Mesh Lawsuit Plaintiffs Seek MDL for Product Liability Claims Involving C.R. Bards Polypropylene Devices, Bernstein Liebhard LLP ReportsHernia Mesh Lawsuit Plaintiffs Seek MDL for Product Liability Claims Involving C.R. Bard's Polypropylene Devices, Bernstein Liebhard LLP Reports
www.prnewswire.com - April 13 at 3:37 PM
Analyzing C R Bard (BCR) and LDR (LDRH)Analyzing C R Bard (BCR) and LDR (LDRH)
www.americanbankingnews.com - March 31 at 7:04 AM
Head-To-Head Review: C R Bard (BCR) versus Palomar Medical Technologies (PMTI)Head-To-Head Review: C R Bard (BCR) versus Palomar Medical Technologies (PMTI)
www.americanbankingnews.com - March 29 at 3:24 AM
Contrasting Given Imaging (GIVN) and C R Bard (BCR)Contrasting Given Imaging (GIVN) and C R Bard (BCR)
www.americanbankingnews.com - March 18 at 5:16 AM
C R Bard Inc (BCR) Given Average Rating of "Hold" by AnalystsC R Bard Inc (BCR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 7 at 1:50 PM
Becton Dickinson Has A Strong, Diverse Pipeline, But Is Fairly Valued, Says BMOBecton Dickinson Has A Strong, Diverse Pipeline, But Is Fairly Valued, Says BMO
finance.yahoo.com - March 6 at 4:54 PM
Contrasting Intersect ENT (XENT) and C R Bard (BCR)Contrasting Intersect ENT (XENT) and C R Bard (BCR)
www.americanbankingnews.com - February 17 at 3:06 AM
C R Bard Inc (BCR) Given Consensus Recommendation of "Hold" by BrokeragesC R Bard Inc (BCR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 10 at 1:38 PM
C R Bard Inc (BCR) Receives Average Rating of "Hold" from AnalystsC R Bard Inc (BCR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 16 at 1:40 PM
KeyBanc Initiates Becton, Dickinson And Co. With Bullish Stance - BenzingaKeyBanc Initiates Becton, Dickinson And Co. With Bullish Stance - Benzinga
www.benzinga.com - January 5 at 1:10 PM
C.R. Bard, Inc. -- Moodys withdraws C.R. Bards ratingsC.R. Bard, Inc. -- Moody's withdraws C.R. Bard's ratings
finance.yahoo.com - January 2 at 11:00 AM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 29, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 29, 2017
finance.yahoo.com - December 29 at 3:45 PM
BD And Bard Expect Proposed Acquisition To Close On Dec. 29BD And Bard Expect Proposed Acquisition To Close On Dec. 29
www.nasdaq.com - December 29 at 11:13 AM
BD Completes Bard Acquisition, Creating New Global Health Care LeaderBD Completes Bard Acquisition, Creating New Global Health Care Leader
finance.yahoo.com - December 29 at 11:13 AM
BD Statement On MOFCOM Clearance Of Bard AcquisitionBD Statement On MOFCOM Clearance Of Bard Acquisition
finance.yahoo.com - December 28 at 2:21 PM
NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018
finance.yahoo.com - December 28 at 2:21 PM
Becton, Dickinson and Company -- Moodys downgrades Becton, Dickinson and Company to speculative gradeBecton, Dickinson and Company -- Moody's downgrades Becton, Dickinson and Company to speculative grade
finance.yahoo.com - December 28 at 2:21 PM
 Analysts Anticipate C.R. Bard, Inc. (BCR) Will Post Earnings of $3.09 Per Share Analysts Anticipate C.R. Bard, Inc. (BCR) Will Post Earnings of $3.09 Per Share
www.americanbankingnews.com - December 28 at 8:18 AM
Becton, Dickinson (BDX) a Step Closer to Bard AcquisitionBecton, Dickinson (BDX) a Step Closer to Bard Acquisition
finance.yahoo.com - December 27 at 11:40 AM
C.R. Bard (BCR) Stock Rating Upgraded by Zacks Investment ResearchC.R. Bard (BCR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - December 26 at 6:28 PM
C.R. Bard, Inc. (New Jersey) – Value Analysis (NYSE:BCR) : December 26, 2017C.R. Bard, Inc. (New Jersey) – Value Analysis (NYSE:BCR) : December 26, 2017
finance.yahoo.com - December 26 at 4:16 PM
FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring C. R. Bard, Inc. (BCR)FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring C. R. Bard, Inc. (BCR)
www.streetinsider.com - December 23 at 3:17 AM
C.R. Bard, Inc. (BCR) VP John A. Deford Sells 14,107 SharesC.R. Bard, Inc. (BCR) VP John A. Deford Sells 14,107 Shares
www.americanbankingnews.com - December 22 at 5:38 PM
Stock Review for Medical Supplies Investors -- CR Bard, Glaukos, Waters, and Cooper - PR Newswire (press release)Stock Review for Medical Supplies Investors -- CR Bard, Glaukos, Waters, and Cooper - PR Newswire (press release)
www.prnewswire.com - December 22 at 5:06 PM
FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring CR ... - StreetInsider.comFTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson (BDX) Acquiring CR ... - StreetInsider.com
www.streetinsider.com - December 22 at 5:06 PM
BD Statement On FTC Clearance Of Bard AcquisitionBD Statement On FTC Clearance Of Bard Acquisition
finance.yahoo.com - December 22 at 5:06 PM
C.R. Bard, Inc. (BCR) Given Consensus Rating of "Hold" by AnalystsC.R. Bard, Inc. (BCR) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 22 at 2:50 PM
C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US : December 22, 2017C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US : December 22, 2017
finance.yahoo.com - December 22 at 11:26 AM
C.R. Bard, Inc. (BCR) Insider Sells $1,127,140.00 in StockC.R. Bard, Inc. (BCR) Insider Sells $1,127,140.00 in Stock
www.americanbankingnews.com - December 18 at 8:36 PM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 18, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 18, 2017
finance.yahoo.com - December 18 at 3:45 PM
C.R. Bard, Inc. (BCR) Insider Sells $4,994,608.00 in StockC.R. Bard, Inc. (BCR) Insider Sells $4,994,608.00 in Stock
www.americanbankingnews.com - December 13 at 5:26 PM
C.R. Bard, Inc. (BCR) Expected to Announce Quarterly Sales of $1.02 BillionC.R. Bard, Inc. (BCR) Expected to Announce Quarterly Sales of $1.02 Billion
www.americanbankingnews.com - December 13 at 12:34 PM
Zacks: Brokerages Expect C.R. Bard, Inc. (BCR) to Post $3.11 Earnings Per ShareZacks: Brokerages Expect C.R. Bard, Inc. (BCR) to Post $3.11 Earnings Per Share
www.americanbankingnews.com - December 11 at 1:24 AM
C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017
finance.yahoo.com - December 8 at 11:30 AM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 7, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 7, 2017
finance.yahoo.com - December 7 at 3:53 PM
C.R. Bard (BCR) Downgraded to "Hold" at ValuEngineC.R. Bard (BCR) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - December 3 at 10:04 PM
How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance?How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance?
finance.yahoo.com - December 3 at 3:46 PM
Financial Comparison: C.R. Bard (BCR) & Sientra (SIEN)Financial Comparison: C.R. Bard (BCR) & Sientra (SIEN)
www.americanbankingnews.com - December 2 at 11:28 AM
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 27, 2017ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 27, 2017
finance.yahoo.com - November 27 at 5:12 PM
C.R. Bard, Inc. (BCR) Receives Average Rating of "Hold" from AnalystsC.R. Bard, Inc. (BCR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 27 at 12:34 PM
Paul Tudor Jones: The Global Macro TraderPaul Tudor Jones: The Global Macro Trader
finance.yahoo.com - November 25 at 3:37 PM
 Brokerages Expect C.R. Bard, Inc. (BCR) Will Post Quarterly Sales of $1.02 Billion Brokerages Expect C.R. Bard, Inc. (BCR) Will Post Quarterly Sales of $1.02 Billion
www.americanbankingnews.com - November 25 at 9:44 AM
C.R. Bard, Inc. (BCR) Expected to Announce Earnings of $3.12 Per ShareC.R. Bard, Inc. (BCR) Expected to Announce Earnings of $3.12 Per Share
www.americanbankingnews.com - November 23 at 3:10 AM
CR Bard (BCR) a Strong Buy on Outstanding Quant Score - Investorplace.comCR Bard (BCR) a Strong Buy on Outstanding Quant Score - Investorplace.com
investorplace.com - November 21 at 4:56 PM
CR Bard (BCR) a Strong Buy on Outstanding Quant ScoreCR Bard (BCR) a Strong Buy on Outstanding Quant Score
investorplace.com - November 21 at 12:06 PM
BD Statement On Merit Medical Agreement To Purchase BD, Bard Product LinesBD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines
finance.yahoo.com - November 16 at 11:54 AM

SEC Filings

C R Bard (NYSE:BCR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

C R Bard (NYSE:BCR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

C R Bard (NYSE BCR) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.